Assel Medressova
Research Subjects
Assel Medressova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Yuriy Pya
University Medical Center (Heart Center, Mother and Child Center, Diagnostic Center), Astana, Kazakhstan
4 shared publicationsSerik Bekbossynov
National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
3 shared publicationsSvetlana Novikova
National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
3 shared publications- Aidyn Kuanyshbek
National Research Cardiac Surgery Center Nur‐Sultan Kazakhstan
2 shared publications - Gulzhan Myrzakhmetova
National Research Cardiac Surgery Center Nur‐Sultan Kazakhstan
2 shared publications - Linar Faizov
National Research Cardiac Surgery Center
2 shared publications
Latest Publications
- 10 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Coronary Arteries Investigation in Normothermic Ex Situ Heart Perfusion Machine
The ex situ heart perfusion technique is noninferior to the standard of care static cold preservation in heart transplantation. It has enabled the expansion of donor criteria and provides reconditioning or treatment as well as diagnostic approaches. Angiography during ex situ heart perfusion is anecdotal but may be useful to evaluating anatomy and somehow coronary physiology on the beating donor heart. The aim of this study was to assess the efficacy and safety of coronary investigation of the beating heart during normothermic ex situ heart perfusion using our institution's unique system. Five domestic adult pigs (90–95 kg, 1–1.5 years of age) were included in the study. After cardiectomy, the pig hearts were connected to the ex situ device, and ex situ angiography and intravascular ultrasound were performed. Cineangiographic images were obtained in different orientations by rotating the C-arm around the heart to find the best angiographic projections for the coronary arteries to be visualized. The results of our study support ex situ coronary arteries evaluation during the normothermic ex situ heart perfusion as a reliable, safe procedure that can be successfully carried out when necessary. The intravascular ultrasound can be used as an adjunctive technology for creating a full picture of the coronary arteries' anatomy.
- 10 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Coronary Arteries Investigation in Normothermic Ex Situ Heart Perfusion Machine
The ex situ heart perfusion technique is noninferior to the standard of care static cold preservation in heart transplantation. It has enabled the expansion of donor criteria and provides reconditioning or treatment as well as diagnostic approaches. Angiography during ex situ heart perfusion is anecdotal but may be useful to evaluating anatomy and somehow coronary physiology on the beating donor heart. The aim of this study was to assess the efficacy and safety of coronary investigation of the beating heart during normothermic ex situ heart perfusion using our institution's unique system. Five domestic adult pigs (90–95 kg, 1–1.5 years of age) were included in the study. After cardiectomy, the pig hearts were connected to the ex situ device, and ex situ angiography and intravascular ultrasound were performed. Cineangiographic images were obtained in different orientations by rotating the C-arm around the heart to find the best angiographic projections for the coronary arteries to be visualized. The results of our study support ex situ coronary arteries evaluation during the normothermic ex situ heart perfusion as a reliable, safe procedure that can be successfully carried out when necessary. The intravascular ultrasound can be used as an adjunctive technology for creating a full picture of the coronary arteries' anatomy.
- 9 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (12) , 4837-4838
Response to the manuscript “ex vivo donor heart preservation in heart transplantation (HTx)—Is this the solution to increase the donor pool?”
- 9 September 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (12) , 4837-4838
Response to the manuscript “ex vivo donor heart preservation in heart transplantation (HTx)—Is this the solution to increase the donor pool?”
- Open Access
- 16 June 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (10) , 1100-1108
First Clinical Experience With the Pressure Sensor–Based Autoregulation of Blood Flow in an Artificial Heart
The CARMAT-Total Artificial Heart (C-TAH) is designed to provide heart replacement therapy for patients with end-stage biventricular failure. This report details the reliability and efficacy of the autoregulation device control mechanism (auto-mode), designed to mimic normal physiologic responses to changing patient needs. Hemodynamic data from a continuous cohort of 10 patients implanted with the device, recorded over 1,842 support days in auto-mode, were analyzed with respect to daily changing physiologic needs. The C-TAH uses embedded pressure sensors to regulate the pump output. Right and left ventricular outputs are automatically balanced. The operator sets target values and the inbuilt algorithm adjusts the stroke volume and beat rate, and hence cardiac output, automatically. Auto-mode is set perioperatively after initial postcardiopulmonary bypass hemodynamic stabilization. All patients showed a range of average inflow pressures of between 5 and 20 mm Hg during their daily activities, resulting in cardiac output responses of between 4.3 and 7.3 L/min. Operator adjustments were cumulatively only required on 20 occasions. This report demonstrates that the C-TAH auto-mode effectively produces appropriate physiologic responses reflective of changing patients’ daily needs and represents one of the unique characteristics of this device in providing almost physiologic heart replacement therapy.
- 16 June 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (10) , 1100-1108
Open AccessFirst Clinical Experience With the Pressure Sensor–Based Autoregulation of Blood Flow in an Artificial Heart
The CARMAT-Total Artificial Heart (C-TAH) is designed to provide heart replacement therapy for patients with end-stage biventricular failure. This report details the reliability and efficacy of the autoregulation device control mechanism (auto-mode), designed to mimic normal physiologic responses to changing patient needs. Hemodynamic data from a continuous cohort of 10 patients implanted with the device, recorded over 1,842 support days in auto-mode, were analyzed with respect to daily changing physiologic needs. The C-TAH uses embedded pressure sensors to regulate the pump output. Right and left ventricular outputs are automatically balanced. The operator sets target values and the inbuilt algorithm adjusts the stroke volume and beat rate, and hence cardiac output, automatically. Auto-mode is set perioperatively after initial postcardiopulmonary bypass hemodynamic stabilization. All patients showed a range of average inflow pressures of between 5 and 20 mm Hg during their daily activities, resulting in cardiac output responses of between 4.3 and 7.3 L/min. Operator adjustments were cumulatively only required on 20 occasions. This report demonstrates that the C-TAH auto-mode effectively produces appropriate physiologic responses reflective of changing patients’ daily needs and represents one of the unique characteristics of this device in providing almost physiologic heart replacement therapy.
- 30 March 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (7) , 2592-2595
Successful heart transplantation after 17 h ex vivo time using the Organ Care System—3 years follow‐up
Cold storage preservation is the standard approach for heart transplantation but is a time‐limited method of care. Ex vivo heart perfusion expands the donor pool due by mitigating time and distance barriers and allows the possibility to improve graft function. We report long term follow up of a successful heart transplantation following an ex vivo time of 17 h using the Organ Care System in a patient with a left ventricular assist device.
- 30 March 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (7) , 2592-2595
Successful heart transplantation after 17 h ex vivo time using the Organ Care System—3 years follow‐up
Cold storage preservation is the standard approach for heart transplantation but is a time‐limited method of care. Ex vivo heart perfusion expands the donor pool due by mitigating time and distance barriers and allows the possibility to improve graft function. We report long term follow up of a successful heart transplantation following an ex vivo time of 17 h using the Organ Care System in a patient with a left ventricular assist device.
- Open Access
- 27 October 2020
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 15 (1) , 1-6
Heart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage
Background: Organ Care System (OCS) minimizes the cold ischemic time and allows for optimization of logistics and meticulous recipient preparation. Impact of normothermic ex-vivo preservation using OCS compared with cold storage (CS) for prolonged heart preservation especially beneficial for high-risk recipients bridged to transplantation with Mechanical Circulatory Support (MCS). Methods: Between 2012 and 2018, we performed a retrospective single-center review of prospectively collected data. All patients who underwent heart transplantation with MCS using the OCS Heart (n = 25) versus standard cold storage (n = 10) were included in this study. Results: During this period, 353 patients were implanted with left ventricular assisted device (LVAD) and 35 (10%) were bridged to heart transplantation. There was no significant difference in donor and recipient characteristics and risk factors. The Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was a trend towards higher estimated risk of death at 1y in the OCS group (14.2 vs. 10.8% p = 0.083). Mean total ischemic time during preservation was statistically significantly longer in CS vs OCS group (210 (23) Vs 74.6 (13) min p = 0.001). Median ex vivo normothermic heart perfusion time in OCS was 348.4(132; 955) min. There was significant difference in total out of body time between OCS group 423(67) Vs CS group 210(23) min p = 0.002). All patients were alive on the 30th days post implant in CS groups and 96% in OCS group (p = 0.5). Conclusion: Normothermic ex-vivo preservation of the allograft during transportation with the organ care system might be beneficial for long-time out of body organ preservation in comparison of cold storage especially for recipients on mechanical circulatory support.
- 27 October 2020
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 15 (1) , 1-6
Open AccessHeart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage
Background: Organ Care System (OCS) minimizes the cold ischemic time and allows for optimization of logistics and meticulous recipient preparation. Impact of normothermic ex-vivo preservation using OCS compared with cold storage (CS) for prolonged heart preservation especially beneficial for high-risk recipients bridged to transplantation with Mechanical Circulatory Support (MCS). Methods: Between 2012 and 2018, we performed a retrospective single-center review of prospectively collected data. All patients who underwent heart transplantation with MCS using the OCS Heart (n = 25) versus standard cold storage (n = 10) were included in this study. Results: During this period, 353 patients were implanted with left ventricular assisted device (LVAD) and 35 (10%) were bridged to heart transplantation. There was no significant difference in donor and recipient characteristics and risk factors. The Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was a trend towards higher estimated risk of death at 1y in the OCS group (14.2 vs. 10.8% p = 0.083). Mean total ischemic time during preservation was statistically significantly longer in CS vs OCS group (210 (23) Vs 74.6 (13) min p = 0.001). Median ex vivo normothermic heart perfusion time in OCS was 348.4(132; 955) min. There was significant difference in total out of body time between OCS group 423(67) Vs CS group 210(23) min p = 0.002). All patients were alive on the 30th days post implant in CS groups and 96% in OCS group (p = 0.5). Conclusion: Normothermic ex-vivo preservation of the allograft during transportation with the organ care system might be beneficial for long-time out of body organ preservation in comparison of cold storage especially for recipients on mechanical circulatory support.
- Open Access
- 15 October 2020
- Published by Springer Nature in Research Square
Heart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage
Background: Organ Care System (OCS) minimizes the cold ischemic time and allows for optimization of logistics and meticulous recipient preparation. Impact of normothermic ex-vivo preservation using OCS compared with cold storage (CS) for prolonged heart preservation especially beneficial for high-risk recipients bridged to transplantation with Mechanical Circulatory Support (MCS).Methods: Between 2012 and 2018, we performed a retrospective single-center review of prospectively collected data. All patients who underwent heart transplantation with MCS using the OCS Heart (n=25) versus standard cold storage (n=10) were included in this study. Results: During this period, 353 patients were implanted with left ventricular assisted device (LVAD) and 35 (10 %) were bridged to heart transplantation. There was no significant difference in donor and recipient characteristics and risk factors. The Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was a trend towards higher estimated risk of death at 1y in the OCS group (14.2 vs. 10.8% p= 0.083). Mean total ischemic time during preservation was statistically significantly longer in CS vs OCS group (210 (23) Vs 74.6 (13) min p=0.001). Median ex vivo normothermic heart perfusion time in OCS was 348.4(132; 955) min. There was significant difference in total out of body time between OCS group 423(67) Vs CS group 210(23) min p=0.002). All patients were alive on the 30th days post implant in CS groups and 96% in OCS group (p=0.5).Conclusion: Normothermic ex-vivo preservation of the allograft during transportation with the organ care system might be beneficial for long-time out of body organ preservation in comparison of cold storage especially for recipients on mechanical circulatory support.
- 15 October 2020
- Published by Springer Nature in Research Square
Open AccessHeart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage
Background: Organ Care System (OCS) minimizes the cold ischemic time and allows for optimization of logistics and meticulous recipient preparation. Impact of normothermic ex-vivo preservation using OCS compared with cold storage (CS) for prolonged heart preservation especially beneficial for high-risk recipients bridged to transplantation with Mechanical Circulatory Support (MCS).Methods: Between 2012 and 2018, we performed a retrospective single-center review of prospectively collected data. All patients who underwent heart transplantation with MCS using the OCS Heart (n=25) versus standard cold storage (n=10) were included in this study. Results: During this period, 353 patients were implanted with left ventricular assisted device (LVAD) and 35 (10 %) were bridged to heart transplantation. There was no significant difference in donor and recipient characteristics and risk factors. The Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was a trend towards higher estimated risk of death at 1y in the OCS group (14.2 vs. 10.8% p= 0.083). Mean total ischemic time during preservation was statistically significantly longer in CS vs OCS group (210 (23) Vs 74.6 (13) min p=0.001). Median ex vivo normothermic heart perfusion time in OCS was 348.4(132; 955) min. There was significant difference in total out of body time between OCS group 423(67) Vs CS group 210(23) min p=0.002). All patients were alive on the 30th days post implant in CS groups and 96% in OCS group (p=0.5).Conclusion: Normothermic ex-vivo preservation of the allograft during transportation with the organ care system might be beneficial for long-time out of body organ preservation in comparison of cold storage especially for recipients on mechanical circulatory support.
- Open Access
- 30 October 2015
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 3 (1) , 26-34
Initial 3-year Outcomes with Left Ventricular Assist Devices in a Country with a Nascent Heart Transplantation Program
Aims The need for the left ventricular assist devices (LVAD) in patients with end-stage heart failure is well established, but prior to 2011, this was not available to patients in Kazakhstan. We describe the development of the sole LVAD programme in the context of a nascent heart transplantation programme and clinical outcomes for the first three years. Methods and results From November 2011 to November 2014, 146 patients underwent implantation of 152 VADs (approximately 50 devices implanted per year). We retrospectively analyzed data from 135 LVAD patients who received HeartMate II (n = 95) or HeartWare (n = 40) devices. In 75 patients LVAD was used as a bridge-to-transplantation and in 60 patients as destination therapy, but only 3 of 135 LVAD patients received heart transplant. Forty-three patients of the LVAD cohort had died by the end of the follow-up period. The mean time on LVAD was 466 ± 330 days (range 5–1200 days). Kaplan–Meier survival estimates for patients who continued on LVAD support were 93% after 1 month, 86% after 6 months and 77% after 12 months. The most common complications within the first 30 days after implant included right ventricular failure (n = 20, 1.85 events/patient-year), renal failure (n = 19, 1.76 events/patient-year) and bleeding (n = 33, 3.0 events/patient-year). Beyond 30 days adverse events included driveline infections (n = 46, 0.56 events/patient-year) and stroke (n = 33, 0.21 events/patient-year). Conclusions LVADs are an important therapeutic alternative to heart transplantation in the context of a developing heart transplant programme with outcomes that are comparable to those reported by other centres.
- 30 October 2015
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 3 (1) , 26-34
Open AccessInitial 3-year Outcomes with Left Ventricular Assist Devices in a Country with a Nascent Heart Transplantation Program
Aims The need for the left ventricular assist devices (LVAD) in patients with end-stage heart failure is well established, but prior to 2011, this was not available to patients in Kazakhstan. We describe the development of the sole LVAD programme in the context of a nascent heart transplantation programme and clinical outcomes for the first three years. Methods and results From November 2011 to November 2014, 146 patients underwent implantation of 152 VADs (approximately 50 devices implanted per year). We retrospectively analyzed data from 135 LVAD patients who received HeartMate II (n = 95) or HeartWare (n = 40) devices. In 75 patients LVAD was used as a bridge-to-transplantation and in 60 patients as destination therapy, but only 3 of 135 LVAD patients received heart transplant. Forty-three patients of the LVAD cohort had died by the end of the follow-up period. The mean time on LVAD was 466 ± 330 days (range 5–1200 days). Kaplan–Meier survival estimates for patients who continued on LVAD support were 93% after 1 month, 86% after 6 months and 77% after 12 months. The most common complications within the first 30 days after implant included right ventricular failure (n = 20, 1.85 events/patient-year), renal failure (n = 19, 1.76 events/patient-year) and bleeding (n = 33, 3.0 events/patient-year). Beyond 30 days adverse events included driveline infections (n = 46, 0.56 events/patient-year) and stroke (n = 33, 0.21 events/patient-year). Conclusions LVADs are an important therapeutic alternative to heart transplantation in the context of a developing heart transplant programme with outcomes that are comparable to those reported by other centres.